**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 58914

**Manuscript Type:** CASE REPORT

**Recurrent medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation: A case report**

Tong MY *et al*. Recurrent MTC treated with RFA

Meng-Ying Tong, Hu-Sha Li, Ying Che

**Meng-Ying Tong, Hu-Sha Li, Ying Che,** Department of Ultrasound, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China

**Author contributions:** Tong MY, Li HS and Che Y contributed to the manuscript writing.

**Corresponding author: Ying Che, MD, PhD, Professor,** Department of Ultrasound, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. cheying@dmu.edu.cn

**Received:** August 14, 2020

**Revised:** November 29, 2020

**Accepted:** December 10, 2020

**Published online:** February 6,2021

**Abstract**

BACKGROUND

Treatment for neck lymph node metastases after adequate initial surgery in medullary thyroid carcinoma (MTC) has been controversial. Ultrasound (US)-guided radiofrequency ablation (RFA) has been widely used in recurrent well-differentiated thyroid carcinoma. Here, we report for the first time the use of RFA in a patient with recurrent MTC.

CASE SUMMARY

We report the case of a 56-year-old woman with cervical lymph node metastases of MTC. Four years previously, she had undergone a total thyroidectomy and neck lymph node dissection. A neck US revealed many enlarged nodes during the follow-up period. Moreover, the serum calcitonin jumped to 198.17 pg/mL, which strongly indicated the recurrence of MTC. Subsequently, two metastatic lymph nodes were confirmed by US-guided fine-needle aspiration-cytology and fine-needle aspiration-calcitonin, and then the patient was treated with RFA. Four months later, the neck US and a contrast-enhanced US showed obvious shrinkage in the ablation zones, and the serum calcitonin dropped to 11.80 pg/mL.

CONCLUSION

This case suggests that RFA may be an effective and safe treatment for local recurrent MTC.

**Key Words:** Medullary thyroid carcinoma; Radiofrequency ablation; Lymph node metastasis; Calcitonin; Fine-needle aspiration; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

Tong MY, Li HS, Che Y. Recurrent medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation: A case report. *World J Clin Cases* 2021; 9(4): 864-870 URL: https://www.wjgnet.com/2307-8960/full/v9/i4/864.htm DOI: https://dx.doi.org/10.12998/wjcc.v9.i4.864

**Core Tip:** Adequate surgery is the mainstay of treatment in medullary thyroid carcinoma. However, neck lymph node metastases after adequate initial treatment are present in a majority of cases. So far, treatment for neck lymph node metastases after adequate initial surgery in medullary thyroid carcinoma has been controversial. Radiofrequency ablation, which is considered a moderate approach between secondary surgery and surveillance, may be attempted for these recurrent patients. This case suggests that radiofrequency ablation may be an effective and safe treatment for local recurrent medullary thyroid carcinoma.

**INTRODUCTION**

The prevalence of medullary thyroid carcinoma (MTC) accounts for approximately 3% to 5% of all thyroid malignancies[1] in sporadic (85% of cases) or hereditary (15% of cases) form[2]. MTC is more aggressive and progressive than well-differentiated thyroid carcinoma and is characterized by early lymph nodal metastases[1,3,4]. Adequate surgery is the mainstay of treatment in MTC. However, neck lymph node metastases after adequate initial treatment are present in the majority of cases[5,6]. In these cases, a second surgical treatment can be considered, but its real therapeutic role is controversial because of the absence of randomized trials comparing reoperation to observation alone. In patients without infiltration of vital neck structures or symptomatic lesions, reoperation may lead to overtreatment and consequential complications[7,8]. Active surveillance management, as an alternative, is not acceptable for many anxious patients. Therefore, radiofrequency ablation (RFA), which is considered a moderate approach between surgery and surveillance, may be attempted for these recurrent patients.

Ultrasound (US)-guided tumor ablation has become a mature treatment for recurrent differentiated thyroid carcinoma[9]. However, to the best of our knowledge, no case has been published that elucidates the efficacy and safety of RFA in local recurrent MTC. We herein describe the outcome of recurrent MTC with neck lymph node metastases treated by RFA in a patient who refused to undergo a second surgery.

**CASE PRESENTATION**

***Chief complaints***

A 56-year-old female presented to the department of ultrasound with recurrent MTC.

***History of present illness***

The patient was diagnosed with sporadic MTC at the age of 51. She presented a hypoechoic solid nodule that was approximately 0.5 cm × 0.4 cm in the left thyroid gland with no pain, diarrhea, flushing or any other specific symptom. The preoperative serum calcitonin was 1165.97 pg/mL. The patient was then treated with total thyroidectomy with central neck dissection and modified left lateral neck dissection. The nodule was pathologically confirmed to be MTC. Nine of fourteen metastatic lymph nodes were found in the excised lymphoid adipose tissue at the left cervical level II-IV, VB and VI (Table 1). Three months after surgery, the serum calcitonin dropped to 11.86 pg/mL (Figure 1).

After the initial treatment, the patient was followed up with neck US, serum calcitonin and carcinoembryonic antigen every 3-6 mo. During the follow-up, an enlarged lymph node (0.4 cm × 0.3 cm) with no visible hilum at left level VI was detected by the neck US in the 9th mo. A similar lymph node (0.5 cm × 0.4 cm) appeared in the left supraclavicular fossa in the 44th mo. In addition, many lymph nodes at the right cervical level II-III and left level V became enlarged. Serum calcitonin jumped to 198.17 pg/mL in the 44th mo. Afterwards, serum calcitonin remained at a high level, which was significantly higher than the reference (Figure 1). The serum carcinoembryonic antigen level had been relatively stable since the initial surgery. The abdominal and lung computed tomography scan revealed no suspicious metastasis.

***Physical examination***

She presented with no lump or tenderness in the neck. Trachea was in the middle of the neck.

***Laboratory examinations***

After the recurrent signs occurred, the patient visited our department for further diagnosis and treatment in the 54th mo. Serum calcitonin was increased at 92.18 pg/mL (normal range: < 15 pg/mL).

***Imaging examinations***

We performed the neck US on the patient, finding six morphologically suspicious lymph nodes. To identify the lymph nodes that harbored metastatic lesions, we conducted US-guided fine-needle aspiration (FNA) on these six nodules. The results of FNA-cytology and FNA-calcitonin are displayed in Table 2. Four of the nodes turned out to be reactive hyperplasia nodes, whereas the other two revealed suspicious malignancy. Moreover, the FNA-calcitonin values of these two suspicious lymph nodes were significantly higher (2000pg/mL) than the others indicating metastatic lesions.

**FINAL DIAGNOSIS**

Postoperative recurrent MTC with metastatic lymph nodes of left VI and left supraclavicular fossa.

**TREATMENT**

After identification of the metastatic lymph nodes (Figure 2A and 2E) by US-guided FNA, we performed RFA on them. The RFA and postoperative contrast-enhanced ultrasound (CEUS) was performed using the LOGIQ E9 Ultrasound System (GE Healthcare, Chicago, IL, United States) with a 9L linear array transducer (6-15 MHz). The ultrasound was conducted using a unipolar RF generator (VIVA RF generator, VRS01; STAR Med Co., Ltd., Korea) and an 18-gauge internally cooled electrode with a 7-mm active tip (VIVA RF Electrode; STAR Med Co., Ltd.). The procedure was performed by a US interventional physician with 15 years of experience in RFA treatment. Briefly, 1% lidocaine was injected for local anesthesia on the puncture point. To prevent thermal injury, saline was injected to isolate the target ablation zone with surrounding tissue, including the trachea, recurrent laryngeal nerves, and supraclavicular nerves (Figure 2B and 2F). Then, the electrode tip was inserted into the lesions (Figure 2C and 2G), fixed at their centers and kept motionless during the ablation procedure. After a short period, transient hyperechoic zones consisting of vapor were observed at the electrode tip (Figure 2D and 2H). During the procedure, the RF generator monitored the temperature at the electrode tip. The power was automatically reduced once the temperature reached 60 ºC.

**OUTCOME AND FOLLOW-UP**

Following the RFA procedure, we immediately performed US and CEUS on the patient. The US revealed two hyperechoic ablated zones that covered the metastatic lesions completely, and CEUS confirmed no enhancement in them (Figure 3A and 3B). No major complications such as intolerable pain, hematoma or nerve injury occurred during or after the treatment. One month after RFA, the patient’s serum calcitonin level dropped to 11.40 pg/mL. Four months later, the neck US and CEUS showed obvious shrinkage in the ablation zones (Figure 3C and 3D), and the serum calcitonin remained at 11.80 pg/mL.

**DISCUSSION**

In this case, we described for the first time the effective use of RFA in the treatment of recurrent MTC with cervical lymph node metastases. The action of RFA, performed with hydrodissection and spot-ablation techniques, performs the main role in coagulating the nodes. After absorption of necrotic tissue, significant shrinkage of metastatic lymph nodes coupled with marked clinical improvement in metastasis-related symptoms was observed. Remarkably, no nerve injuries or inflammatory changes induced by RFA were encountered, which is a critical advantage as compared to a secondary surgery.

RFA has been recently used to treat patients with metastatic lymph nodes from recurrent papillary thyroid carcinoma[10,11] and primary papillary thyroid microcarcinoma without cervical lymph node metastasis[12-15]. Complete disappearance of the whole lesion was reported in the majority of cases during the follow-up periods. In terms of safety, few major complications have been encountered, demonstrating the safety of RFA[11]. Therefore, RFA is an acceptable treatment to manage both primary papillary thyroid microcarcinoma and metastatic lymph nodes from papillary thyroid carcinoma in terms of efficacy and safety for nonsurgical candidates.

RFA for recurrent MTCs has not been reported in the literature. However, for the present case, in which the patient had undergone an initial complete surgery and then postoperative lymph nodes metastasized, we decided to perform RFA on the patient for the following reasons. First, because the recurrent MTC did not appear to infiltrate vital neck structures or symptomatic lesions, reoperation may have led to overtreatment and produced negative complications[7,8]. Second, adhesions or inflammatory changes induced by the initial surgery may produce difficulties for the secondary surgery. Third, the patient was very anxious, and active surveillance management was deemed unacceptable. Fourth, the patient refused to undergo a second surgery.

To perform RFA, a critical issue is to accurately identify the metastatic lymph nodes. Calcitonin measurement in FNA washout has been suggested as a useful supplement to conventional FNA-cytology in patients with metastatic MTC or increased serum calcitonin[16-19]. The cut-off level for FNA-calcitonin has been reported to range from 10.4 to 67 pg/mL[19-22]. Specifically, Kihara *et al*[21] reported that when the cut-off value was 21.0 pg/mL, FNA-calcitonin had the highest sensitivity and specificity (nearly 100%), noting the contrast with approximately 45%-63% sensitivity of routine FNA-cytology[23,24]. In this case, FNA-calcitonin of the lymph nodes at left level VI and left supraclavicular fossa were significantly higher (> 2000 pg/mL) than the other lymph nodes, despite the negative FNA-cytology result, indicating that these two lymph nodes were responsible for the persistent increase in serum calcitonin.

After identifying the metastatic lymph nodes, we conducted RFA on these two lesions. In our patient, after two insertions of an RF electrode using a spot ablation technique, the lesions were completely ablated as indicated by the postoperative CEUS and follow-up sonography evaluations. These imaging changes in the lesions were accompanied by a clinically significant decline in serum calcitonin values. Overall, this case provides evidence to support the mainstay role of RFA in the treatment of local recurrent MTC. As a local minimally invasive therapy, RFA is an acceptable treatment for managing metastatic lymph nodes in MTC in terms of efficacy and safety, which is necessary in prolonging disease-free survival time and delaying systemic therapy. Moreover, a greater number of patients and a long follow-up period should be employed to elucidate the long-term efficacy of RFA.

**CONCLUSION**

To the best of our knowledge, this is the first case study of RFA in the treatment of local recurrent MTC. The effective and safe response suggests the possibility that RFA may be a novel option to control local recurrent MTC, warranting clinical verifications with larger sample sizes.

**REFERENCES**

1 **Viola D**, Elisei R. Management of Medullary Thyroid Cancer. *Endocrinol Metab Clin North Am* 2019; **48**: 285-301 [PMID: 30717909 DOI: 10.1016/j.ecl.2018.11.006]

2 **Wells SA Jr**, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid* 2015; **25**: 567-610 [PMID: 25810047 DOI: 10.1089/thy.2014.0335]

3 **Elisei R**, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. *Nat Rev Endocrinol* 2012; **8**: 466-475 [PMID: 22473335 DOI: 10.1038/nrendo.2012.38]

4 **Meng K**, Luo H, Chen H, Guo H, Xia W. Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: A population-based study using the SEER 18 database. *Medicine (Baltimore)* 2019; **98**: e13884 [PMID: 30608412 DOI: 10.1097/MD.0000000000013884]

5 **Fialkowski E**, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. *World J Surg* 2008; **32**: 754-765 [PMID: 18188643 DOI: 10.1007/s00268-007-9317-7]

6 **Tisell LE**, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. *Surgery* 1986; **99**: 60-66 [PMID: 3942001]

7 **Miccoli P**, Minuto MN, Ugolini C, Molinaro E, Basolo F, Berti P, Pinchera A, Elisei R. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. *Endocr Relat Cancer* 2007; **14**: 1099-1105 [PMID: 18045961 DOI: 10.1677/ERC-07-0128]

8 **Scollo C**, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. *J Clin Endocrinol Metab* 2003; **88**: 2070-2075 [PMID: 12727956 DOI: 10.1210/jc.2002-021713]

9 **Mauri G**, Cova L, Ierace T, Baroli A, Di Mauro E, Pacella CM, Goldberg SN, Solbiati L. Treatment of Metastatic Lymph Nodes in the Neck from Papillary Thyroid Carcinoma with Percutaneous Laser Ablation. *Cardiovasc Intervent Radiol* 2016; **39**: 1023-1030 [PMID: 26911732 DOI: 10.1007/s00270-016-1313-6]

10 **Baek JH**, Kim YS, Sung JY, Choi H, Lee JH. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. *AJR Am J Roentgenol* 2011; **197**: W331-W336 [PMID: 21785061 DOI: 10.2214/AJR.10.5345]

11 **Chung SR**, Suh CH, Baek JH, Park HS, Choi YJ, Lee JH. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis. *Int J Hyperthermia* 2017; **33**: 920-930 [PMID: 28565997 DOI: 10.1080/02656736.2017.1337936]

12 **Zhang Y**, Zhang MB, Luo YK, Li J, Zhang Y, Tang J. Effect of chronic lymphocytic thyroiditis on the efficacy and safety of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma. *Cancer Med* 2019; **8**: 5450-5458 [PMID: 31359613 DOI: 10.1002/cam4.2406]

13 **Kim JH**, Baek JH, Sung JY, Min HS, Kim KW, Hah JH, Park DJ, Kim KH, Cho BY, Na DG. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery. *Int J Hyperthermia* 2017; **33**: 212-219 [PMID: 27590679 DOI: 10.1080/02656736.2016.1230893]

14 **Jeong SY**, Baek JH, Choi YJ, Chung SR, Sung TY, Kim WG, Kim TY, Lee JH. Radiofrequency ablation of primary thyroid carcinoma: efficacy according to the types of thyroid carcinoma. *Int J Hyperthermia* 2018; **34**: 611-616 [PMID: 29322881 DOI: 10.1080/02656736.2018.1427288]

15 **Zhang M**, Luo Y, Zhang Y, Tang J. Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma: A Prospective Study. *Thyroid* 2016; **26**: 1581-1587 [PMID: 27445090 DOI: 10.1089/thy.2015.0471]

16 **Boi F**, Maurelli I, Pinna G, Atzeni F, Piga M, Lai ML, Mariotti S. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 2007; **92**: 2115-2118 [PMID: 17405835 DOI: 10.1210/jc.2007-0326]

17 **Kudo T**, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. *Thyroid* 2007; **17**: 635-638 [PMID: 17696833 DOI: 10.1089/thy.2006.0338]

18 **Abraham D**, Gault PM, Hunt J, Bentz J. Calcitonin estimation in neck lymph node fine-needle aspirate fluid prevents misinterpretation of cytology in patients with metastatic medullary thyroid cancer. *Thyroid* 2009; **19**: 1015-1016 [PMID: 19678738 DOI: 10.1089/thy.2009.0011]

19 **Trimboli P**, Cremonini N, Ceriani L, Saggiorato E, Guidobaldi L, Romanelli F, Ventura C, Laurenti O, Messuti I, Solaroli E, Madaio R, Bongiovanni M, Orlandi F, Crescenzi A, Valabrega S, Giovanella L. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. *Clin Endocrinol (Oxf)* 2014; **80**: 135-140 [PMID: 23627255 DOI: 10.1111/cen.12234]

20 **de Crea C**, Raffaelli M, Maccora D, Carrozza C, Canu G, Fadda G, Bellantone R, Lombardi CP. Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma. *Acta Otorhinolaryngol Ital* 2014; **34**: 399-405 [PMID: 25762832]

21 **Kihara M**, Hirokawa M, Kudo T, Hayashi T, Yamamoto M, Masuoka H, Higashiyama T, Fukushima M, Ito Y, Miya A, Miyauchi A. Calcitonin measurement in fine-needle aspirate washout fluid by electrochemiluminescence immunoassay for thyroid tumors. *Thyroid Res* 2018; **11**: 15 [PMID: 30450128 DOI: 10.1186/s13044-018-0059-4]

22 **Trimboli P**, Crescenzi A, Saggiorato E, Treglia G, Giovanella L. Novel acquisitions in the diagnosis of medullary thyroid carcinoma. *Minerva Endocrinol* 2017; **42**: 238-247 [PMID: 27808486 DOI: 10.23736/S0391-1977.16.02579-7]

23 **Elisei R**, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. *J Clin Endocrinol Metab* 2004; **89**: 163-168 [PMID: 14715844 DOI: 10.1210/jc.2003-030550]

24 **Bugalho MJ**, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. *J Surg Oncol* 2005; **91**: 56-60 [PMID: 15999359 DOI: 10.1002/jso.20269]

**Footnotes**

**Informed consent statement:** Informed consent was obtained from the participant included in the study.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016) and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 14, 2020

**First decision:** November 26, 2020

**Article in press:** December 10, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Hansen AW **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Yuan YY


**Figure Legends**



**Figure 1 Changes of serum calcitonin and carcinoembryonic antigen levels at each follow-up visit after the initial surgery.** The dashed lines indicate reference values. CEA: Carcinoembryonic antigen; CT: Calcitonin; RFA: Radiofrequency ablation.



**Figure 2 Ultrasound-guided radiofrequency ablation process.** A-D: Lymph nodes at left level VI; E-H: Lymph nodes at left supraclavicular fossa; A and E: Ultrasound (US) images of pre-radiofrequency ablation (RFA); B and F: US images of the hydrodissection process. Saline was injected to form an edema zone (circled by the dashed line), isolating the target ablated zones with nerves, trachea (marked with star) and skin; C and G: US images of insertion with the electrode tip; D and H: US images of the radiofrequency ablation procedure.The single arrows point to the lymph nodes of the target. The double arrows point to the RF electrode. CA: Carotid artery.



**Figure 3 Images of ultrasound and contrast-enhanced ultrasound after the radiofrequency ablation.** A and B: Images captured immediately after radiofrequency ablation (RFA); C and D: Images 4 mo after RFA. The arrows point to ablated lymph nodes. Pentagram (marked with star): Trachea. CA: Carotid artery.

**Table 1** **Pathology of cervical lymph nodes in the initial surgery**

|  |  |  |
| --- | --- | --- |
| Level | Number of metastasis | Total number |
| Left II | 1 | 3 |
| Left III | 1 | 1 |
| Left IV | 1 | 3 |
| Left VB | 0 | 0 |
| Left VI | 6 | 7 |
| Total | 9 | 14 |

**Table 2 Results of fine-needle aspiration-cytology and fine-needle aspiration-calcitonin**

|  |  |  |
| --- | --- | --- |
| Location/level (size) | Cytological pathology | FNA-calcitonin, pg/mL |
| Right/II | Reactive hyperplasia | < 2.00 |
| Right/III | Reactive hyperplasia | < 2.00 |
| Left/V (5.0 mm × 3.0 mm) | Reactive hyperplasia | < 2.00 |
| Left/V (7.9 mm × 4.1 mm) | Reactive hyperplasia | < 2.00 |
| Left/VI1 | No tumor cell found | > 2000 |
| Left/supraclavicular fossa1 | A few epithelioid cells | > 2000 |

1Metastatic lymph nodes suggested by both fine-needle aspiration (FNA)-cytology and FNA-calcitonin.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**